Thomas J Withers, 67Brighton Twp, MI

2021001, Jan 14, 2021

Mar 14, 2019

16/980198

- Huntington WV, US
Meagan W. Valentine - Huntington WV, US
Richard M. Niles - Huntington WV, US
Thomas Ryan Withers - Huntington WV, US
Brandon D. Kirby - Huntington WV, US

C12R 1/38
C08L 5/04
C12N 1/20

Bacterial cultures are provided that comprise a modified bacterium missing or deficient in two or more virulence factors. The two or more virulence factors can be selected from exotoxin A, hemolytic phospholipase C, phenazine-specific methyltransferase, alpha-1,3-rhamnosyltransferase, and 3-phosphoshikimate 1-carboxyvinyltransferase. Certain of the modified bacteria are also missing or deficient in one or more alginate acetylation enzymes including the alginate Oacetyltransferases AlgI, AlgJ, AlgF, AlgX, and/or the C5-mannuronan epimerase AlgG. Methods of producing alginate are also provided along with compositions comprising alginate produced by the modified bacteria.

2019036, Dec 5, 2019

Jun 3, 2019

16/429153

- Huntington WV, US
Thomas Ryan Withers - Huntington WV, US
Brandon Kirby - Bluefield WV, US

A61K 31/437
A61K 9/00
A61K 31/7036

Methods of treating a bacterial lung infection are provided and comprise administering an effective amount of rifaximin to a subject in need thereof. The rifaximin can be delivered by inhalation therapy, such as by delivering the rifaximin in aerosol form. The rifaximin is administered alone or in combination with tobramycin, including in multiple doses. Methods of reducing biofilm formation are also provided and comprise contacting a bacteria with an effective amount of rifaximin. Pharmaceutical composition are also included and comprise rifaximin and a pharmaceutically-acceptable vehicle suitable for administering the rifaximin in aerosol form.